Developing novel complement activation assays for application in basic and clinical research
Studying the cross-talk between complement and TLRs, in particular to the co-receptor CD14
Investigating the effect on inflammation by inhibiting complement activation and CD14 using human whole blood in vitro models and in vivo animal models of human diseases
Studying the “Thromboinflammation” and new complex whole blood models to reveal cross-talk between biological systems ex vivo
Studying complement activation in patients with diseases being tentative candidates for future complement intervention
Develop tools for evaluation of the effect of complement therapy in the clinic
Andersson LI, Sandgren P, Sjöström DJ, Mohlin C, Hägerström K, Tjernberg I, Mollnes TE, Nilsson PH(2025) Complement C3 inhibition reduces complement activation in clinical platelet concentrates but does not counteract platelet storage lesions Platelets, 36(1), 2513298 DOI 10.1080/09537104.2025.2513298, PubMed 40566731
Cyranka L, Mariegaard I, Fageräng B, Pérez-Alós L, Harpf V, Mollnes TE, Garred P, Rosbjerg A(2025) Inhibition of Alternative and Terminal Complement Pathway Components Modulate the Immune Response Against Bacteria and Fungi in Whole Blood Scand J Immunol, 101(5), e70030 DOI 10.1111/sji.70030, PubMed 40387159
Damoah CE, Valderhaug SM, Snir O, Hindberg KD, Brækkan SK, Grover SP, Nøst TH, Gál P, Pál G, Jonasson C, Garred P, Mollnes TE, Hveem K, Hansen JB(2025) Elevated Plasma MBL Levels Are Associated With Risk of Future Venous Thromboembolism: The HUNT Study Arterioscler Thromb Vasc Biol, 45(7), e324-e335 DOI 10.1161/ATVBAHA.124.322052, PubMed 40371468
